Neuregulin-1 Administration Protocols Sufficient for Stimulating Cardiac Regeneration in Young Mice Do Not Induce Somatic, Organ, or Neoplastic Growth

PLoS ONE, 2016 · DOI: 10.1371/journal.pone.0155456 · Published: May 13, 2016

Cardiovascular Science Genetics Regenerative Medicine & Stem Cells

Simple Explanation

This research investigates whether using neuregulin-1 (rNRG1), a growth factor known to help regenerate heart tissue in young mice, causes unwanted growth in other parts of the body. The study found that even at doses higher than those used in human trials, rNRG1 did not cause increased growth of organs, body mass, or tumors in mice. These findings suggest that rNRG1 could be a potential therapy for pediatric heart failure without causing systemic growth issues, but further studies are needed to confirm this in humans.

Study Duration

6 Months

Participants

Mice (ICR strain)

Evidence Level

Not specified

Key Findings

1
Administration of rNRG1 did not alter somatic growth, as measured by body weight and tibia length.
2
MRI scans showed that rNRG1 administration did not alter the volume of the lungs, liver, kidneys, brain, or spinal cord.
3
No neoplastic growth or microscopic neoplastic foci were observed in rNRG1-treated mice through MRI, visual inspection, and histopathological analyses.

Research Summary

The study investigates the potential extra-cardiac growth effects of rNRG1 in mice, complementing a prior presentation of a therapeutic strategy for rNRG1 administration in pediatric patients. Results indicate that rNRG1 administration protocols sufficient for stimulating cardiomyocyte cycling and cardiac regeneration do not induce somatic, organ, or neoplastic growth in mice. The absence of rNRG1-induced organ growth can be explained by the lack of increased S6 kinase phosphorylation, indicating that rNRG1 administration does not activate cellular mechanisms of protein synthesis.

Practical Implications

Therapeutic Potential for Pediatric Heart Failure

rNRG1 may be a viable therapeutic option for pediatric heart failure due to its ability to stimulate cardiac regeneration without inducing unwanted growth effects.

Safety Profile

The study provides preliminary evidence supporting the biosafety of rNRG1 administration, suggesting it does not induce extra-cardiac growth effects in young mice.

Further Research

Further animal and human studies are needed to establish a comprehensive safety profile and fully understand the potential risks and benefits of rNRG1 therapy.

Study Limitations

1
Study conducted on mice, and results may not directly translate to humans.
2
Further studies may be required to determine whether this is the case in a corresponding human population.
3
Further animal and human studies are required to establish a comprehensive safety profile.

Your Feedback

Was this summary helpful?

Back to Cardiovascular Science